Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity

Proposed mechanism. A Doxorubicin (DOX) targets the BCAA catabolic pathway in TNBCs, by downregulating BCKDK and augmenting clearance of intracellular BCKAs. B Genetic or pharmacological (high BT2 concentration) inhibition of BCKDK results in increased cell death, decreased intracellular BCKAs, dysr...

Full description

Bibliographic Details
Main Authors: Dipsikha Biswas, Logan Slade, Luke Duffley, Neil Mueller, Khoi Thien Dao, Angella Mercer, Shanmugasundaram Pakkiriswami, Yassine El Hiani, Petra C. Kienesberger, Thomas Pulinilkunnil
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00602-0